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Esophageal cancer is often diagnosed at an advanced stage, with many patients found to have locoregional or metastatic disease
at time of diagnosis. Because of this, cure may be unlikely, leading treatment eﬀorts to focus more on symptom palliation and
improving patient quality of life. The majority of patients with advanced disease suﬀer from some degree of dysphagia. Palliative
eﬀorts are therefore directed at relieving dysphagia, allowing patients to manage their oropharyngeal secretions, reduce aspiration
risk, and maintain caloric intake orally. A variety of endoscopic treatment modalities have been utilized with these objectives in
mind, with options determined by the location and size of the tumor, as well as the patient’s expected prognosis. In this article, we
review the use of endoscopically-placed stents for palliation in patients with advanced esophageal cancer. We discuss the history
of stent use in such cases, as well as more recent developments in stent technology. We give an overview of some of the more
commonly used stents in practice, discuss the technique of insertion, and survey the short- and long-term outcomes of stent
placement.
1.Introduction
Esophageal cancer is a relatively rare form of cancer with
an estimated 482,300 new cases in 2008 worldwide. The
incidence rates of esophageal cancer vary greatly based on
region, with the highest rates found in Asia, including
China and Central Asia, and in Africa [1]. The USA is a
relatively low-incidence area for carcinoma of esophagus,
with approximately 16,640 new cases and 14,500 deaths in
2010 [2]. Most carcinomas of esophagus are diagnosed at an
advanced stage, with very few patients eligible for potentially
curative resection at the time of presentation, leaving
palliation as a more realistic option for these patients [3].
Dysphagia is the predominant symptom in more than 70%
of patients with esophageal cancer resulting in weight loss
and malnutrition [4]. Other symptoms include aspiration of
saliva (due to complete dysphagia) or food (secondary to
esophagorespiratory ﬁstulae), and thoracic pain caused by
the invasion of an unresectable tumor. These symptoms have
led to the development of a variety of treatment modalities
to help maintain caloric intake and improve the quality of
life remaining for patients with advanced disease. Presently,
a number of endoscopy-based modalities are utilized to
palliate these symptoms and will be covered in this paper.
2.Background
The primary goal of esophageal stent insertion in patients
with advanced disease is to relieve dysphagia and to prevent
malnutrition. Compared to parenteral nutrition, endoscopic
stent placement signiﬁcantly improves a patient’s quality
of life by restoring the ability to take in food and ﬂuids
orally. Speciﬁc indications include intraluminal obstruc-
tion due to tumor, extrinsic esophageal compression due
to primary or secondary tumors, refractory or recurrent
esophageal strictures, malignant esophageal perforation, tra-
cheoesophageal ﬁstula, gastroesophageal anastomotic leaks,
and tumor recurrence after surgery or chemoradiotherapy
(Table 1, Figures 1 and 2)[ 5–7].
Historically,esophagealintubationforobstructiondueto
tumor was achieved with the use of rigid polyvinyl plastic
stents, either per oral pulsion or using an open traction
technique, which required a laparotomy and gastrostomy.2 ISRN Gastroenterology
Figure 1: Barium swallow after stent deployment for a mides-
ophageal stricture due to malignancy.
Although eﬀective in more than 80% of patients, plastic
stents were associated with complications such as migration,
food impaction and perforation in up to 10% of patients
[8]. Since the introduction of uncovered self-expanding
metal stents (SEMSs) in the early 1990s, plastic stents have
rarely been utilized. SEMS placement was found to provide
immediate palliation of dysphagia in greater than 85% of
patients when evaluated with a standard dysphagia scoring
system [9–11]. According to a meta-analysis by Yakoub,
compared to plastic stents, metal stents are associated with
signiﬁcantly reduced stent-related mortality (1.7% versus
11.1%), reduced esophageal perforation (1.4% versus 9.4%),
and stent migration. On the other hand, tumor ingrowth
through the open mesh architecture may occur in 13% of
SEMS cases compared to 1.6% for when plastic stents are
used [12, 13]. In response to this, the next generation of
partially covered self-expanding metal stents, which added
a thin silicone or plastic covering to the body of the stent
to prevent tumor ingrowth was developed. Soon after it was
observed that hypertrophic granulation at the uncovered
ends of the stent prevented repositioning or removal of
stents,makingthempracticalonlyforpalliationofmalignant
dysphagia, as stents could not be adjusted [14], this led to
theintroductionoffullycoveredself-expandingplasticstents
(SEPS) in 2001. These initial SEPS exerted more radial force
than their metal counterparts, causing patients some degree
of discomfort. More recently, newer fully covered SEMS have
been developed as an alternative due to this shortcoming.
3.StentSelection
There are several commercially available expandable metal
stentsintheUnitedStates.EsophagealSEMScanbeclassiﬁed
based on (1) covering (partially versus fully covered),
(2) alloy material (nitinol (alloy of 55% nickel and 45%
titanium) versus surgical steel versus plastic polyvinyl), (3)
function (fully patent versus antireﬂux), and (4) biodegrad-
ability. Once malignant dysphagia has been diagnosed, the
stricture must ﬁrst be characterized; stent selection is then
(a)
(b)
Figure 2: Endoscopic appearance after placement of Alimaxx stent
placement. (a) shows proximal extent of stent. (b) shows reveals
stent architecture.
Table 1: Indications and contraindications for stent use in
esophageal obstruction due to malignancy.
Indications
Unresectable malignant esophageal obstruction
Extrinsic esophageal compression by primary or secondary
mediastinal tumors
Actual or impending ﬁstula
Malignant gastroesophageal anastomotic leaks
Tumor recurrence after surgery or chemoradiotherapy
Contraindication to chemoradiotherapy
Contraindications
Curable disease by multimodality treatment (relative)
Tumor or stricture within 2cm of proximal esophageal sphincter
Uncorrectable coagulopathy
Potential for signiﬁcant airway compression
Recent high-dose chemoradiotherapy (within 3–6 weeks)
Terminal ill patient with limited life expectancy
Sources: [5, 6].
tailored to the patient based on the tumor’s characteristics.
SEMS come in diﬀerent diameters, lengths, and deployment
mechanisms that need to be considered based on several
variables related to the tumor.ISRN Gastroenterology 3
3.1. Tumor Length. Tumor margins must be determined
either endoscopically or with an esophagram. The stent must
be long enough to bridge the stricture and the propensity
for tumor growth around the ends must be considered.
Speciﬁcally, the stent should extend 2–4cm beyond the ends
ofthestricturetominimizethechancesoftumorovergrowth
at the ends of the stent.
3.2. Tumor Bulk. The luminal diameter of the obstructing
tumor must allow for passage of the stent-introducer
catheter. In some cases, dilatation is required to allow stent
passage.Thesmallapplicatorsizeoftheself-expandingmetal
stents requires less aggressive dilation.
3.3. Tumor Location. Midesophageal lesions are best suited
for stenting. Nevertheless, stents can be also placed in
the distal esophagus (albeit with increased risk of gastric
reﬂux, regurgitation, and aspiration), and in the proximal
esophagus (though the tumor must be more than 2 cm from
the upper esophageal sphincter). In a small series of patients,
a newly designed SEMS with a short upper ﬂange (0.7cm
in length) was used in the treatment of proximal/cervical
esophageal cancers. Stent placement was successful in these
patients with no serious complications [15]. Another area
of debate is the routine use of SEMS with an antireﬂux
valve in the management of malignant dysphagia due to
distal esophageal and gastric cardia malignancy; presently,
the use of stents with an antireﬂux valve remains has yielded
inconsistent results regarding eﬃcacy of reﬂux prevention
among recent studies [7].
3.4. Conﬁguration of the Obstructive Stricture. The tortuosity
of malignant strictures can pose a challenge for stent
placement, since stents tend to ﬁt best in strictures that
allow the stent to remain relatively straight. Tortuosity was
more problematic with early plastic stents due to their
poor ﬂexibility. Modern stents are more ﬂexible, allowing
retention of luminal patency in very tortuous strictures, with
less local trauma.
3.5. The Presence of Tracheoesophageal Fistulas. Covered
stents can be eﬀective at occluding the ﬁstula tracts caused
by locally invasive malignancy, facilitating closure [3].
4. Stent Devices
( i )S E M Sa r ea v a i l a b l ea su n c o v e r e d ,p a r t i a l l yc o v e r e d ,o r
fully covered (Table 2). There is clinical evidence to suggest
that partially covered SEMS are superior to uncovered SEMS,
in the palliation of unresectable obstructive esophageal
cancer, mainly because tumor ingrowth through uncovered
stents results in recurrent dysphagia. Vakil and colleagues
reported on 62 patients in a prospective, multicentric,
randomized, controlled trial. Thirty patients with malignant
inoperable esophageal obstruction at the gastroesophageal
junction were treated with uncovered stents, while 32
patients with comparable disease were treated with cov-
ered stents. One week after stenting the dysphagia scores
improved similarly in both treatment arms. However, tumor
ingrowth was signiﬁcantly more likely in the uncovered stent
group (9/30) than in the covered group (1/32) (P = 0.005).
Reinterventions for tumor ingrowth were also signiﬁcantly
greater in the uncovered stent group (27%), as compared
with 0% in the covered group (P = 0.002) [16]. Similarly,
in another study 2 diﬀerent types of SEMS (uncovered
nitinol Strecker and covered ultraﬂex stents) were compared
in the palliative treatment of 152 patients with inoperable
malignant stenosis of the esophagus and cardia. Overall 88%
of patients with covered stents and 54% with uncovered
stents were free of symptoms during followup (P<0.0001).
Restenosis causing recurrent dysphagia were signiﬁcantly
higherinpatientswithuncoveredstentscomparedtocovered
stents (37% versus 8%, P<0.0001) despite lower rates of
stent migration (0 versus 10%, P = 0.03) [17].
(ii) Self-expanding plastic stents (SEPSs) have been
widely used for the palliation of esophageal cancer over the
last decade, since they combine the advantages of SEMS
with those of previously used plastic stents. In a prospective
cohort study of 33 patients with malignant esophageal stenos
treated palliatively with the SEPS, improvement of dysphagia
was noticed in all cases. Stent occlusion occurred due to
tumor overgrowth in 12.1%, stent migration was observed
in 6.0%, and the reintervention rate was 21.1% [18].
Another group of investigators reported their experience on
60 patients with esophageal obstruction due to esophageal
cancer (n = 52), lung cancer (n = 7), and thyroid tumor
(n = 1), treated with the Polyﬂex stent. Early minor
complications (e.g., chest pain, fever, gastroesophageal reﬂux
symptoms, and incomplete usage of stent) occurred in
32% of patients, while major complications (including 3
deaths, one occurring due to pulmonary embolism and two
after massive hemorrhage) were seen in 22%. Delayed stent
m i g r a t i o no c c u r r e di n5p a t i e n t sa n dt u m o ro v e r g r o w t h
occurred in 8 patients. The mean dysphagia score of 2.8
improved to a mean score of 1.0 after stenting (P<0.001)
[19]. In another case series of 66 patients with unresectable
esophageal cancer, the SEPS Polyﬂex was used; in all patients
in this study, the insertion of SEPSs led to an improvement
in dysphagia. Additionally, the rate of tumor overgrowth and
stent migration were low in this cohort [20].
All SEMS are delivered in a compressed form, which
allows the delivery system to have a relatively small diameter
compared with the ﬁnal stent diameter after deployment.
Many of the stents are preloaded onto the delivery system,
though some require loading immediately prior to the
procedure. The delivery systems vary in size from 6 to
14mm. All delivery system have radio-opaque markers
indicating the limits of the compressed stent as well as the
expected stent length when fully expanded. Below is an
overview of some of the most common SEMS and SEPS
available.
(i) Ultraﬂex (Boston Scientiﬁc, Boston, Mass, USA) is a
constructionmeshSEMSknittedfromasinglestrand
of nitinol wire; it is available in two forms: uncovered
and the covered, where the body of the stent is
covered by sheath of polyurethane. The stent is kept4 ISRN Gastroenterology
Table 2: Esophageal stents currently on the market in the USA, Europe, and Asia.
Stent Manufacturer Material Covering Length (cm) Diameter shaft/ﬂare (mm) Antireﬂux valve FDA
approved
Alimaxx-ES Alveolus Nitinol FC 7/10/2012 18,22 No Yes
Choostent MI Tech Nitinol FC 5 ∼ 20 18,20,22 Yes (valve variant) Yes
Esophageal Z Cook Stainless steel PC/FC 8/10/12/14 18/25 Yes (Dua variant) Yes
Evolution Cook Nitinol PC
8/10/12.5/15 18/23 (FC)
No Yes (PC) 8/10/12 (FC) 20/25 (PC,FC)
FerX-Ella Ella-CS Stainless steel FC 9/10.5/12/13.5
15/16.5/18/ 19.5 /21
20/36 Yes/No No
Flamingo
Wallstent Boston Scientiﬁc Stainless steel PC 12/14 20/30 No No
Gianturco Z Cook Stainless steel PC 8/10/12/14 18/25 Yes No
No; shaft bars No
Niti-S Taewoong
Medical Nitinol PC/FC 3/5/7/9/12 16/24 Yes (PTFE variant) Yes
18/26
20/28
Polyﬂex Boston Scientiﬁc Polyester FC 9/12/2015 16/20 No Yes
18/23
21/28
Ultraﬂex NG Boston Scientiﬁc Nitinol NC/PC 7/10/12/15 18,23 No Yes
Wallﬂex Boston Scientiﬁc Nitinol PC/FC 10/12/15
PC 18/23 FC 18/25
No Yes 23/28 23/28
NC, not covered; PC, partially covered; FC, fully covered; FDA, Food and Drug Administration.
compressed along a supple plastic guide by means of
a coiled thread around the stent. Once this thread
is pulled, the stent self-expands to its ﬁnal diameter.
It may be placed without ﬂuoroscopy by using a
ruler on the shaft of the delivery system to measure
visual markers. It is an extremely ﬂexible SEMS but
has the lowest expansile force of all available metal
prostheses; as a result, the stent may need to be
dilated with a balloon to achieve adequate expansion.
(ii) Flamingo Wallstent (Boston Scientiﬁc, Boston, Mass,
USA) has a conical or funnel-shaped design, con-
structed from a braided stainless steel alloy. This
conical shape provides greater radial expansion prox-
imally, in order to reduce migration across the
esophagogastric junction. This is an older device and
is no longer available in the USA.
(iii) Wallﬂex (Boston Scientiﬁc, Boston, Mass, USA) is a
newer generation of SEMSs. It is available as fully
and partially covered stent. Unlike other stents, the
fully covered the Wallﬂex may be reconstrained up
to 75% of deployment and up to two times during
initialstentplacementprocedure.Italsoincorporates
a purse string Teﬂon coated polyester suture at the
proximal end which facilitates stent repositioning
or removal. This stent also has “progressive step
ﬂared ends” that theoretically reduces migration by
anchoring the stent within the esophageal lumen.
(iv) Evolution (Cook, Bloomington, Ind, USA) is avail-
able as a partially or fully covered SEMS. The stent
is encased with silicone on its exterior and interior
surfaces to prevent tumor ingrowth. Additionally, the
fully covered version incorporates a dual purse string
“lasso loop” on the proximal and distal ends of the
stent to aid in repositioning, if needed. A unique
feature of Evolution delivery system is that it enables
a controlled release and recapturability feature with a
“point of no return” indicator. With each squeeze of
the stent system’s trigger-based introducer, a propor-
tional length of the stent is deployed or recaptured.
(v) Alimaxx-E (Merit Medical Systems, UT) is a laser cut
nitinol stent, fully coated with polyurethane on the
exterior and silicone lining. It contains “antimigra-
tion struts” that project along the length of the stent
in an eﬀort to prevent migration.
(vi) Niti-S (Taewoond Medical, Korea) has a double-layer
conﬁguration consisting of an inner polyurethane
layer to prevent tumor overgrowth and an outer
uncovered nitinol wire tube to allow the mesh of the
stent to embed itself in the esophageal wall.
(vii) Polyﬂex (Boston Scientiﬁc, Boston, Mass, USA)
consist of polyester netting completely covered in a
silicone membrane. The device must be loaded onto
the delivery system prior to deployment.ISRN Gastroenterology 5
5. Technique of Insertion
In general, image guidance with plain X-ray ﬂuoroscopy
is suﬃcient for successful stent placement, while a hybrid
approach with endoscopy may be used in technically
challenging cases. In our institution, we prefer the hybrid
approach. The patient is placed supine and either moderate
conscious sedation or general anesthesia is induced. Flexible
esophagoscopy is performed to characterize the lesion. Then,
using ﬂuoroscopic guidance, the proximal and distal extent
of the tumor is marked on the skin using radiopaque metal
markers. If the endoscope cannot be passed through the
tumor, dilation is performed. A guidewire is placed through
the tumor, and the delivery system is inserted over the wire.
The stent is deployed across the tumor length previously
delineatedbytheradiopaquemarkers.Balloondilationofthe
stent may be performed if the stent has a low expansile force
and has not expanded suﬃciently.
6.PostprocedureCare
After placement of any esophageal stent and before reinsti-
tution of oral feeding, an X-ray of the chest and a contrast-
enhanced esophagography with dilute barium are performed
to rule out perforation and to ensure the correct position
of the prosthesis. Nutritional instructions are given to the
patients to avoid food impaction within the stents. Usually,
patients are allowed oral feeding 12 hours post-procedure in
order to allow adequate time to detect any procedure-related
complications. Diet is usually started as soft or liquid; diets
high in ﬁber and large meals are avoided. Drinking with
meals is recommended to wash away any food remnants.
Patients with esophageal stents should not lie down ﬂat; they
are advised to eat in an upright position and to sleep at a
30-degree angle. A proton pump inhibitor is recommended
for all patients who develop reﬂux after stent deployment
and in those where the stent is placed across the GE junction
[6].
7. ClinicalOutcomes
The optimum management of malignant dysphagia has
evolved over the past two decades, with SEMS playing a
greater role in the palliation of advanced esophageal cancer.
Since the early 1990s, metal stents have replaced rigid plastic
stents as they have been found to be more cost eﬀective
and safer, with fewer associated complications [12, 13, 21].
In a randomized controlled, prospective trial by Knyrim
and colleagues, 39 patients with esophageal carcinoma and
3 with malignant extrinsic obstruction were randomized
to either a 16mm diameter plastic prosthesis (Wilson-
Cook, Winston-Salem, NC, USA) or an expandable metal-
mesh stent (Wallstent, Schneider AG, Switzerland) made of
stainless steel. In this study, the complication rates were
signiﬁcantly less frequent with the metal stents than with
the plastic prostheses (0 versus 9; P<0.001). There were
similar degrees in improvement in dysphagia and Karnofsky
score between treatment arms. The most common causes of
recurrent dysphagia were migration of the plastic prostheses
(n = 5 patients), or an ingrowth or overgrowth of the metal
stents by tumor (n = 5 patients). The authors concluded
that despite having a higher initial cost, metal stents were
ultimately more cost eﬀective because of the absence of
fatal complications and the decrease in the hospital stay
associated with their use [13]. In another randomized,
controlled study, 31 patients with inoperable malignant
esophageal stenosis causing dysphagia were randomized to
receive either a modiﬁed Gianturco SEMS or a plastic
Atkinson tube; again,there were similar complication rates
observed between the two groups. Nevertheless, compared
to patients who received Atkinson plastic tubes, patients
with Gianturco SEMS had better palliation of dysphagia
(median dysphagia score 1 versus 2, P = 0.04), maintained
their weight longer, had shorter hospital stays, and had a
longer survival rate [22] .Am o r er e c e n tr e t r o s p e c t i v er e v i e w
of 153 patients (45 with plastic prostheses and 108 with
SEMS) also showed an improvement in dysphagia, survival,
with comparable recurrent dysphagia rates between the two
groups. However, signiﬁcantly more major complications
were seen in the plastic prosthesis group compared with
the SEMS group [23]. In summary, SEMS have shown
to be superior to rigid plastic prostheses in the palliative
management of unresectable obstructive esophageal cancers
[7].
The ease of insertion and high technical success rate
associated with SEMS account for their widespread use [24].
They may provide instant dysphagia relief in up to 96% of
patients while improving dysphagia scores by 1-2 grades.
Despite the various types of stents available there is no
apparent superiority among diﬀerent stents with regards of
dysphagia relief [21, 25–30]. In a prospective randomized
controlled trial, Sabharwal and colleagues compared the
rate of early and late complications (perforation, migration,
severe gastroesophageal reﬂux, hematemesis, and reobstruc-
tion due to tumor overgrowth) in 53 patients diagnosed with
inoperable lower third esophageal carcinoma randomized to
receive either a ﬂamingo covered wallstent (Boston Scientiﬁc
Inc., Watertown, Mass, USA) or an Ultraﬂex covered stent
(Boston Scientiﬁc Inc.) for palliation. In both stent groups,
there was a signiﬁcant improvement in dysphagia (P<0.05)
butnosigniﬁcantdiﬀerencewasseenbetweenthetwogroups
(P>0.1). The frequency of complications among the groups
was similar [31]. In another prospective randomized study,
Siersema compared the placement of an Ultraﬂex stent, a
Flamingo Wallstent or a Gianturco-Z stent in a group of
100 patients with esophagogastric carcinoma. All 3 covered
m e t a ls t e n t so ﬀered the same degree of palliation (P<
0.001) with no diﬀerence in the degree of improvement
among the groups (P = 0.014). Placement of Gianturco-
Z stents, although not statistically signiﬁcant (P = 0.23),
was associated with more complications (36%) compared
with Ultraﬂex stents (33%) and Flamingo Wallstents (24%)
[32].
Palliative stenting is associated with a reintervention rate
of approximately 25%–35%, requiring close followup of
these patients in order to maintain eﬀective palliation. The
median and mean survival after stent placement ranges from
approximately 78–83 days and 120–126 days, respectively,6 ISRN Gastroenterology
regardless of the type of stent used. Survival has not been
associated with the etiology of the malignancy or the type of
stent used; rather, it is related to the progression of disease
[9, 12].
While typically used for palliation in patients with
unresectable or metastatic disease, esophageal stenting has
also been used in patients receiving neoadjuvant therapy
forpatientsawaitingdeﬁnitivesurgicaltreatment.Compared
to feeding tubes, removable self-expanding silicone stents
allows for maintenance of preoperative enteral nutrition
while avoiding the need for operatively placed j-tubes. In
some small series, its use in the neoadjuvant setting has
been shown to be safe and eﬀective without an adverse
eﬀect on intraoperative dissection, perioperative compli-
cations, or delay in resection after neoadjuvant therapy
[33–35].
8. Comparing Self-ExpandableMetal (SEMSs)
andSelf-Expandable Plastic(SEPSs)Stents
One of the drawbacks of the currently generation of stents is
the phenomenon of recurrent dysphagia due to stent migra-
tion and tissue growth. Tumor ingrowth, initially noted in
ﬁrst generation of uncovered SEMS, led to the development
of other options including new self-expandable plastic stents
(SEPS). A recent prospective, randomized controlled trial
compared the new SEPS (Polyﬂex) with SEMS (Ultraﬂex) in
a 100 patients with unresectable esophageal carcinoma; stent
placement was successful in 98% and 100%, respectively.
In multivariate analysis, there was a signiﬁcantly higher
complication rate with Polyﬂex than with Ultraﬂex stents
(odds ratio 2.3, 95% CI 1.2–4.4). No diﬀerence was seen in
palliation of dysphagia between the two stents. The median
survival was 134 days with Polyﬂex and 122 days with
Ultraﬂexstents(P = NS).Inanotherstudy,125patientswith
dysphagia from inoperable carcinoma of the esophagus or
gastric cardia were randomized to placement of an Ultraﬂex
(N = 42), Polyﬂex stent (N = 41), or Niti-S stent (N =
42). Improvement of dysphagia was comparable between all
three stent groups. However, recurrent dysphagia, caused
by tissue ingrowth, migration, or food obstruction, was
signiﬁcantly diﬀerent between patients with an Ultraﬂex
stent and patients with a Polyﬂex stent or Niti-S stent
(52% versus 37% versus 31%, P = 0.03). Stent migration
occurred more frequently with Polyﬂex stents which were
also associated with more technical diﬃculties during actual
stent placement.
T h er a t eo ft i s s u eo v e r g r o w t hw a sm o r eh i g h e rw i t h
Ultraﬂex stents, and to a lesser degree, Niti-S stents, but
not statistically signiﬁcant [36]. No diﬀerence in survival
was found between cohorts. On the basis of the technical
diﬃculties and high stent migration rates, the investigators
concluded that SEPS was the least preferable stent in
this patient group. The majority of recent studies suggest
that despite the comparable eﬃcacy in the treatment of
dysphagia between SEMSs and SEPSs, SEMSs are associated
with signiﬁcantly fewer complications than SEPSs for the
palliation of malignant dysphagia.
9.Comparing SEMSswithOther Modalities
Despite the advances in therapeutic modalities and tech-
niques, the optimal method of palliation for unresectable
esophageal cancer patients remains uncertain and is not
standardized. Compared to plastic tube insertion, SEMS
provide better palliation of dysphagia, reduced recurrent
dysphagia, decreased initial hospital stay, and procedure-
related morbidity and mortality [5, 6, 12, 13]. Thermal
and chemical ablative modalities such as photodynamic
therapy (PDT) and laser provide a level of palliation
comparable to that achieved with SEMSs. However, the
increased rate of reinterventions associated with their use
makes PDT a less desirable option [37]. Brachytherapy
has been found to palliate dysphagia eﬀectively in patients
with advanced esophageal cancer, providing a sustained
improvement in dysphagia symptoms and quality of life over
time. Brachytherapy is also associated with a low incidence
of complications, making it a very suitable alternative to
SEMS insertion in the palliation of patients with advanced
esophageal and gastroesophageal junction cancers. However,
this diﬀerence gradually diminishes after 12 months and the
optimal dosage and fractional schedule is still uncertain [38–
40].
10. Complications
Insertion of SEMS is not without its share of complications.
While early complications are relatively uncommon, delayed
complications can occur in up to 53%–65% of patients, with
a reintervention rate as high as 50% [41–43]. Approximately
0.5%–2% of patients die as direct result of expandable stent
placement. Prior radiotherapy or chemotherapy contributes
toasigniﬁcantlyhigherrateoflife-threateningcomplications
and mortality rate after stent insertion [44, 45].
Some of the most common early procedure-related
complications include chest pain, bleeding, perforation, and
aspiration. Prolonged chest pain is reported in 12%–14%
of cases after SEMS insertion and is more prominent when
stents are placed in the upper cervical esophagus, and with
stents having either a high radial force, such as Wallstent,
or a ﬂared design such as the Flamingo stent. A small
amount of bleeding 24 to 48 hours after SEMSs insertion
is relatively common and is usually due to direct trauma
during the procedure. Lung aspiration secondary to chronic
gastroesophageal reﬂux can occur during stent placement
and as a result of stent positioning across one of the
esophagealsphincters.Theseproblemscanbeaddressedwith
the newer regeneration of stents, speciﬁcally those with an
antireﬂux valve, coupled with strict medical management
of GERD with aggressive acid suppression and antireﬂux
precautions. The risk of perforation or stent erosion into
adjacent structures is rare but has been described. It occurs
more frequently in patients whose tumors were previously
treatedwithchemotherapy,radiation,orlasertherapy.When
recognized early it can be treated with a covered stent and
administration of antibiotics [22, 41, 43, 45–48].
Delayed complications include tumor ingrowth or over-
growth, stent migration, recurrent dysphagia, intractableISRN Gastroenterology 7
reﬂux, tracheoesophageal ﬁstula, bleeding, and perforation.
Stent obstruction with recurrent dysphagia may be due to
tumor progression, reactive hyperplasia or food impaction
[45]. Tumor ingrowth through the mesh is most commonly
seen in uncovered stents and should not occur in covered
SEMS. Overgrowth of the stent by tumor may occur in
4%–18% of cases [43]. It can occur at either end of a
covered or an uncovered stent, underlying the importance
of choosing the appropriate stent length (with a minimum
of 2cm beyond the proximal and distal margins of the
tumor).Insuchcases,tumorov ergro wthma ybetreatedwith
ablative therapies such as laser and photodynamic therapy
or with a second stent deployment. Covered stents have a
reportedly higher incidence of stent migration with series
reporting as high as 23% compared to uncovered stents,
which have a rate of approximately 8.7% [22, 42, 46]. It is
usually more common when the stent is positioned across
the gastroesophageal junction. Other factors contributing to
stentmigrationarestentmalposition,shrinkageofthetumor
from chemotherapy or radiation therapy, or overdilation
of the lesion before stent placement [45]. Stent removal
either surgically or endoscopically after complete migration
is only indicated for symptomatic patients [49]. Partial
stent migration is treated with coaxial insertion of another
overlapping stent. A few cases of ﬁstula formation and
tracheal compression have been reported, especially in case
of stent placement in the upper and mid-third of the
esophagus [50–52]. Bleeding can also occur due to stent
erosion into vessels within the esophageal wall. Perforation
may occur and is thought to result from pressure necrosis
caused by the continuing radial force of the stent on the
tumor or from the stent struts penetrating through the
esophageal wall.
11.FutureTechnology
There are a number of future trends on the horizon with
regards to stent technology. Removable SEPSs have been
introduced for use in benign and malignant strictures, as
well as for postesophagectomy complications. Biodegradable
stents made of polylactic polymers have recently been
utilized, and though experience with this is limited, they
have shown some eﬃcacy in the management of refractory
benign esophageal strictures after endoscopic submucosal
dissection [53–55]. More recently, drug-eluting esophageal
stents have introduced in treatment of refractory benign and
malignant strictures, as they provide mechanical support as
well as release of drugs to prevent restenosis by inhibiting
tissue hyperplasia [56, 57].
12. Conclusion
Palliation of esophageal malignant dysphagia can be chal-
lenging and often requires a multidisciplinary approach
for optimal success. Esophageal stenting has been shown
to be a safe and eﬀective tool for refractory dysphagia.
Recent advances in stent technology have reduced peri- and
postprocedural complications, resulting in improved quality
of life for these patients. Because of this, esophageal stents
havebecomethetherapyofchoiceforpalliationofdysphagia
with further investigation aimed at providing continued and
p r o l o n g e dr e l i e fo fs y m p t o m s .
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